莱美药业
(300006)
| 流通市值：47.30亿 | | | 总市值：47.30亿 |
| 流通股本：10.56亿 | | | 总股本：10.56亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 979,958,406.36 | 849,957,381.82 | 1,072,103,854.7 | 1,094,166,065.67 |
| 应收票据及应收账款 | 256,868,835.89 | 271,866,863.92 | 274,340,379.12 | 290,463,042.24 |
| 其中：应收票据 | 1,514,084.32 | 1,658,528.48 | 1,858,428.88 | 1,213,588.88 |
| 应收账款 | 255,354,751.57 | 270,208,335.44 | 272,481,950.24 | 289,249,453.36 |
| 应收款项融资 | 12,590,437.14 | 22,768,985.93 | 12,331,592.71 | 4,316,241.06 |
| 预付款项 | 32,286,967.28 | 36,457,128.11 | 31,571,312.8 | 62,305,098.39 |
| 其他应收款合计 | 136,331,121.68 | 154,383,981.81 | 166,748,697.84 | 187,962,033.07 |
| 存货 | 177,671,971.76 | 188,688,328.5 | 201,698,756.58 | 192,671,799.83 |
| 其他流动资产 | 6,742,798.42 | 8,247,626.99 | 11,304,413.99 | 9,093,007.77 |
| 流动资产合计 | 1,602,450,538.53 | 1,532,370,297.08 | 1,770,099,007.74 | 1,840,977,288.03 |
| 非流动资产: | | | | |
| 长期股权投资 | 235,424,680.32 | 241,121,244.03 | 220,174,591.57 | 221,145,639.02 |
| 其他权益工具投资 | 140,728,359.96 | 158,106,229.96 | 158,106,229.96 | 269,869,388.16 |
| 投资性房地产 | 3,214,883.81 | 3,063,881.36 | 2,348,928.19 | 847,989.19 |
| 固定资产 | 247,189,273.14 | 252,212,784.43 | 259,757,107.28 | 263,559,545.43 |
| 在建工程 | 7,116,771.79 | 7,079,657.68 | 6,997,965.44 | 10,445.87 |
| 使用权资产 | 8,446,410.99 | 9,712,625.78 | 8,209,912.06 | 9,355,875.31 |
| 无形资产 | 184,900,941.8 | 181,045,877.32 | 181,829,793.69 | 188,030,054 |
| 开发支出 | 45,380,486.11 | 36,698,204.31 | 35,442,929.19 | 30,163,072.81 |
| 商誉 | 44,945,322.9 | 44,937,983.41 | 44,945,322.9 | 44,937,983.41 |
| 长期待摊费用 | 4,697,089.6 | 4,772,714.05 | 4,916,636.49 | 4,819,357.79 |
| 递延所得税资产 | 131,106,534.22 | 130,436,155.29 | 128,239,753.53 | 134,209,296.5 |
| 其他非流动资产 | 29,646,099.3 | 39,911,639.32 | 34,731,493.5 | 28,850,670.96 |
| 非流动资产合计 | 1,082,796,853.94 | 1,109,098,996.94 | 1,085,700,663.8 | 1,195,799,318.45 |
| 资产总计 | 2,685,247,392.47 | 2,641,469,294.02 | 2,855,799,671.54 | 3,036,776,606.48 |
| 流动负债: | | | | |
| 短期借款 | 210,957,025 | 137,700,000 | 242,914,255.8 | 174,437,510.01 |
| 应付票据及应付账款 | 67,546,759.4 | 63,159,451.82 | 65,620,494.34 | 48,002,864.15 |
| 应付账款 | 67,546,759.4 | 63,159,451.82 | 65,620,494.34 | 48,002,864.15 |
| 合同负债 | 17,283,582.3 | 13,663,128.24 | 13,793,241.5 | 17,028,080.87 |
| 应付职工薪酬 | 17,484,609.7 | 17,653,643.23 | 38,170,302.69 | 18,762,912.67 |
| 应交税费 | 5,984,604.9 | 10,266,184.17 | 9,608,923.04 | 17,478,405.87 |
| 其他应付款合计 | 262,993,453.62 | 284,539,305.67 | 323,456,338.37 | 402,798,655.19 |
| 一年内到期的非流动负债 | 120,104,201.02 | 94,472,228.87 | 106,403,640.05 | 101,268,808.04 |
| 其他流动负债 | 2,091,488.08 | 1,622,879.43 | 1,645,681.76 | 2,118,586.29 |
| 流动负债合计 | 704,445,724.02 | 623,076,821.43 | 801,612,877.55 | 781,895,823.09 |
| 非流动负债: | | | | |
| 长期借款 | 85,050,000 | 115,800,000 | 141,450,000 | 118,700,000 |
| 租赁负债 | 3,112,738.72 | 4,026,018.27 | 3,825,675.44 | 4,602,457.61 |
| 递延收益 | 5,636,263.44 | 6,160,749.07 | 6,292,097.25 | 4,548,199.43 |
| 递延所得税负债 | 19,180,735.94 | 19,247,305.9 | 19,287,005.11 | 19,519,349.9 |
| 非流动负债合计 | 112,979,738.1 | 145,234,073.24 | 170,854,777.8 | 147,370,006.94 |
| 负债合计 | 817,425,462.12 | 768,310,894.67 | 972,467,655.35 | 929,265,830.03 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 1,055,911,205 | 1,055,911,205 | 1,055,911,205 | 1,055,911,205 |
| 资本公积 | 1,484,545,509.33 | 1,483,237,810.03 | 1,483,237,810.03 | 1,483,415,825.37 |
| 其他综合收益 | -162,525,734.57 | -162,525,734.57 | -162,525,734.57 | -43,771,919.62 |
| 盈余公积 | 54,026,897.56 | 54,026,897.56 | 54,026,897.56 | 54,026,897.56 |
| 未分配利润 | -578,738,419.13 | -569,130,295.25 | -555,354,972.73 | -493,967,655.63 |
| 归属于母公司股东权益合计 | 1,853,219,458.19 | 1,861,519,882.77 | 1,875,295,205.29 | 2,055,614,352.68 |
| 少数股东权益 | 14,602,472.16 | 11,638,516.58 | 8,036,810.9 | 51,896,423.77 |
| 股东权益合计 | 1,867,821,930.35 | 1,873,158,399.35 | 1,883,332,016.19 | 2,107,510,776.45 |
| 负债和股东权益合计 | 2,685,247,392.47 | 2,641,469,294.02 | 2,855,799,671.54 | 3,036,776,606.48 |
| 公告日期 | 2025-08-22 | 2025-04-24 | 2025-03-22 | 2024-10-23 |
| 审计意见(境内) | | | 标准无保留意见 | |